tyrosinase peptide

Phase 3Peptide

EEastern Cooperative Oncology Group

tyrosinase peptide is one of 80 biologic programs targeting Iris Melanoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Iris MelanomaCompleted

Metastatic MelanomaActive, not recruiting

MelanomaActive, not recruiting

Iris MelanomaPhase 3

Completed

Metastatic MelanomaPhase 1/Phase 2

Active, not recruiting

MelanomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

947 competitors in Melanoma

#DrugCompanyPhaseTrials

Leukine

Sanofi

Phase 3

21 2

Proleukin

IIovance Biotherapeutics, Inc.

Phase 3

27 3

Libtayo

Regeneron

Phase 3

6 4

Imjudo

AstraZeneca

Phase 3

2 5

Tuoyi

SSun Yat-sen University

Phase 3

4 6

Incomplete Freund's Adjuvant

EEastern Cooperative Oncology Group

Phase 3

20 7

Deltavit

HHyundai Pharmaceutical Co., LTD.

Rhuph20

1 9

Epacadostat

Incyte

Phase 3

1 10

tyrosinase peptide

EEastern Cooperative Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Melanoma15 trials

Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery

Completed·UUniversity of Southern California·Phase 1·NCT00025181·19 enrolled

Vaccine Therapy in Treating Patients With Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT00003665·40 enrolled

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00085189·42 enrolled

Show 12 more trials

Vaccine Therapy Followed by Biological Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 2·NCT00006113·25 enrolled

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT00005633

Vaccine Therapy With or Without Interleukin-12 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00003339·48 enrolled

Vaccine Therapy in Treating Patients With Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00020358

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00031733·60 enrolled

Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma

Completed·UUniversity of Virginia·Phase 2·NCT00003222·40 enrolled

Vaccine Therapy Plus Immune Adjuvants in Treating Patients With Advanced Melanoma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT00003362

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00089063·40 enrolled

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

Completed·UUniversity of Southern California·Phase 2·NCT00003274·48 enrolled

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

Terminated·UUniversity of Southern California·Phase 1·NCT00005841·15 enrolled

Vaccine Therapy in Treating Patients With Melanoma of the Eye

Terminated·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 3·NCT00036816·13 enrolled

Vaccine Therapy and Sargramostim in Treating Patients With Stage IV Malignant Melanoma

Completed·NNational Cancer Institute (NCI)·N/A·NCT00006243·30 enrolled

Metastatic Melanoma7 trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·BBaylor Health Care System·Phase 1·NCT00003792

Vaccine Therapy With or Without Sargramostim in Treating Patients With High-Risk or Metastatic Melanoma

Unknown status·HHerbert Irving Comprehensive Cancer Center·Phase 1·NCT00037037

Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma

Completed·EEastern Cooperative Oncology Group·Phase 2·NCT00006385

Show 4 more trials

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Completed·UUniversity of Southern California·Phase 2·NCT00334776·6 enrolled

Vaccine Therapy in Treating Patients With Metastatic Melanoma Who Are Undergoing Surgery for Lymph Node and Tumor Removal

Completed·—·Phase 1/2·NCT00003229

Vaccine Therapy in Treating Patients With Recurrent or Refractory Metastatic Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019383

flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer

Completed·NNational Cancer Institute (NCI)·Phase 2·NCT00019396

Iris Melanoma1 trial

A Randomized, Placebo-Controlled Phase III Trial of Yeast Derived GM-CSF Versus Peptide Vaccination Versus GM-CSF Plus Peptide Vaccination Versus Placebo in Patients With "No Evidence of Disease" After Complete Surgical Resection of "Locally Advanced" and/or Stage IV Melanoma

Completed·NNational Cancer Institute (NCI)·Phase 3·NCT01989572·815 enrolled

Sources

References

[1]
ClinicalTrials.gov — 23 trial records for tyrosinase peptide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — tyrosinase peptide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for tyrosinase peptide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eastern Cooperative Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: EEastern Cooperative Oncology Group

tyrosinase peptide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Melanoma15 trials

Metastatic Melanoma7 trials

Iris Melanoma1 trial

References

Drug Info

Quick Facts

Related News